Article Text

Download PDFPDF
Losartan reduced stroke and new onset diabetes more than atenolol in essential hypertension with signs of left ventricular hypertrophy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

OpenUrlCrossRefPubMedWeb of Science

QUESTION: In patients with essential hypertension and signs of left ventricular hypertrophy (LVH), is losartan based treatment more effective than atenolol based treatment?


Randomised (unclear allocation concealment), blinded (patients and monitoring committee), controlled trial with ≥4 years of follow up.


Multicentre trial in Europe and the US.


9222 patients 55–80 years of age (mean age 67 y, 54% women) with hypertension (sitting blood pressure [BP] of 160–200 mm Hg systolic, 95–115 mm Hg diastolic, or both after 1–2 wks of placebo) and electrocardiographic signs of LVH. Exclusion criteria included secondary hypertension; myocardial infarction (MI) or stroke within the …

View Full Text


  • Source of funding: Merck.

  • For correspondence: Professor B Dahlöf, Sahlgrenska University Hospital/Östra, Gothenburg, Sweden. bdahlof{at}

  • A modified version of this abstract appears in ACP Journal Club.